601 related articles for article (PubMed ID: 15054499)
1. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors.
Perini R; Fiorucci S; Wallace JL
Can J Gastroenterol; 2004 Apr; 18(4):229-36. PubMed ID: 15054499
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal effects of nonsteroidal anti-inflammatory drugs.
Whittle BJ
Fundam Clin Pharmacol; 2003 Jun; 17(3):301-13. PubMed ID: 12803569
[TBL] [Abstract][Full Text] [Related]
4. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
Hochberg MC
Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
[TBL] [Abstract][Full Text] [Related]
5. Gastroprotective and ulcer healing effects of nitric oxide-releasing non-steroidal anti-inflammatory drugs.
Brzozowski T; Konturek PC; Konturek SJ; Sliwowski Z; Drozdowicz D; Kwiecień S; Pajdo R; Ptak A; Pawlik M; Hahn E
Dig Liver Dis; 2000 Oct; 32(7):583-94. PubMed ID: 11142556
[TBL] [Abstract][Full Text] [Related]
6. COX-2-Selective NSAIDs: new and improved?
Lichtenstein DR; Wolfe MM
JAMA; 2000 Sep; 284(10):1297-9. PubMed ID: 10980759
[No Abstract] [Full Text] [Related]
7. Efficacy of cyclooxygenase-2-specific inhibitors.
Cannon GW; Breedveld FC
Am J Med; 2001 Feb; 110 Suppl 3A():6S-12S. PubMed ID: 11173044
[TBL] [Abstract][Full Text] [Related]
8. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
Simon LS; Weaver AL; Graham DY; Kivitz AJ; Lipsky PE; Hubbard RC; Isakson PC; Verburg KM; Yu SS; Zhao WW; Geis GS
JAMA; 1999 Nov; 282(20):1921-8. PubMed ID: 10580457
[TBL] [Abstract][Full Text] [Related]
9. Dual acting anti-inflammatory drugs: a reappraisal.
Bertolini A; Ottani A; Sandrini M
Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
[TBL] [Abstract][Full Text] [Related]
10. Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited.
Lichtenberger LM
Biochem Pharmacol; 2001 Mar; 61(6):631-7. PubMed ID: 11266647
[TBL] [Abstract][Full Text] [Related]
11. NSAIDs: gastroprotection or selective COX-2 inhibitor?
Dickman A; Ellershaw J
Palliat Med; 2004 May; 18(4):275-86. PubMed ID: 15198117
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors.
Buttgereit F; Burmester GR; Simon LS
Am J Med; 2001 Feb; 110 Suppl 3A():13S-9S. PubMed ID: 11173045
[TBL] [Abstract][Full Text] [Related]
13. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks.
Bertolini A; Ottani A; Sandrini M
Curr Med Chem; 2002 May; 9(10):1033-43. PubMed ID: 12733982
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibitors of COX-2--are they safe for the stomach?
Giercksky KE; Haglund U; Rask-Madsen J
Scand J Gastroenterol; 2000 Nov; 35(11):1121-4. PubMed ID: 11145280
[TBL] [Abstract][Full Text] [Related]
15. [Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects].
Blain H; Jouzeau JY; Netter P; Jeandel C
Rev Med Interne; 2000 Nov; 21(11):978-88. PubMed ID: 11109595
[TBL] [Abstract][Full Text] [Related]
16. Current perspective on the cardiovascular effects of coxibs.
Konstam MA; Weir MR
Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293
[TBL] [Abstract][Full Text] [Related]
17. COX-2 specific inhibitors offer improved advantages over traditional NSAIDs.
Urban MK
Orthopedics; 2000 Jul; 23(7 Suppl):S761-4. PubMed ID: 10914695
[TBL] [Abstract][Full Text] [Related]
18. Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor.
Muscará MN; McKnight W; Asfaha S; Wallace JL
Br J Pharmacol; 2000 Feb; 129(4):681-6. PubMed ID: 10683192
[TBL] [Abstract][Full Text] [Related]
19. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
Geis GS
Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic potential of NO-NSAIDs.
Wallace JL; Del Soldato P
Fundam Clin Pharmacol; 2003 Feb; 17(1):11-20. PubMed ID: 12588626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
